STEVIE (Safety Events In VIsmodEgib), a single-arm, open-label study on the safety of Hedgehog Pathway Inhibitors in advanced basal cell carcinoma Vismodegib: interim analysis of 150 patients

被引：0
|
作者：
Gutzmer, Ralf [1 ]
Leverkues, Martin [2 ,3 ]
Garbe, Claus [4 ]
Herbst, Rudolf [5 ]
Schadendorf, Dirk [6 ]
Kunstfeld, Rainer [7 ]
Hansson, Johan [8 ]
Basset-Seguin, Nicole [9 ]
Page, Damian [10 ]
Mitchell, Lada [10 ]
Hauschild, Axel [11 ]
机构：
[1] Hannover Med Sch, Hannover, Germany
[2] Univ Med Mannheim, Mannheim, Germany
[3] Univ Heidelberg, Med Fak Mannheim, D-6800 Mannheim, Germany
[4] Univ Klin Tubingen, Tubingen, Germany
[5] HELIOS Hauttumorzentrum, Erfurt, Germany
[6] Univ Klinikum Essen, Essen, Germany
[7] Med Univ Wien, Vienna, Austria
[8] Karolinska Univ Spital, Stockholm, Sweden
[9] Hop St Louis, Paris, France
[10] F Hoffmann La Roche & Cie AG, Basel, Switzerland
[11] Univ Klinikum Schleswig Holstein, Kiel, Germany
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2012年 / 10卷 / 09期
关键词：
D O I：
10.1111/j.1610-0387.2012.08008.x
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：677 / 677
页数：1
相关论文
共 50 条
  • [21] A pivotal multicenter trial evaluating efficacy and safety of the hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with advanced basal cell carcinoma
    Sekulic, Aleksandar
    Oro, Anthony E.
    Solomon, James A.
    Hainsworth, John D.
    Lewis, Karl
    Dirix, Luc
    Migden, Michael R.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB149 - AB149
  • [22] Analysis of efficacy and safety of vismodegib therapy in patients with advanced basal cell carcinoma - real world multicenter cohort study
    Slowinska, M.
    Dudzisz-Sledz, M.
    Sobczuk, P.
    Lasinska, I
    Pietruszka, A.
    Cybulska-Stopa, B.
    Kowalczyk, A.
    Switaj, T.
    Czarnecka, I
    Kosela-Paterczyk, H.
    Rogala, P.
    Paluchowska, E.
    Skladowski, K.
    Mackiewicz, J.
    Rutkowski, P.
    Owczarek, W.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (08) : 1219 - 1228
  • [23] Phase II Open-Label, Single-Arm Trial to Investigate the Efficacy and Safety of Topical Remetinostat Gel in Patients with Basal Cell Carcinoma
    Kilgour, James M.
    Shah, Aatman
    Urman, Nicole M.
    Eichstadt, Shaundra
    Do, Hanh N.
    Bailey, Irene
    Mirza, Amar
    Li, Shufeng
    Oro, Anthony E.
    Aasi, Sumaira Z.
    Sarin, Kavita Y.
    CLINICAL CANCER RESEARCH, 2021, 27 (17) : 4717 - 4725
  • [24] A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma
    Sofen, Howard
    Gross, Kenneth G.
    Goldberg, Leonard H.
    Sharata, Harry
    Hamilton, Tiffani K.
    Egbert, Barbara
    Lyons, Benjamin
    Hou, Jeannie
    Caro, Ivor
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 73 (01) : 99 - U180
  • [25] Vismodegib improves quality of life in patients with periocular locally advanced basal cell carcinoma: subgroup analysis, STEVIE trial
    Assaf Gershoni
    Alon Tiosano
    Meydan Ben Ishai
    Edward Barayev
    Guy J. Ben Simon
    Iftach Yassur
    Eye, 2022, 36 : 407 - 413
  • [26] Vismodegib improves quality of life in patients with periocular locally advanced basal cell carcinoma: subgroup analysis, STEVIE trial
    Gershoni, Assaf
    Tiosano, Alon
    Ben Ishai, Meydan
    Barayev, Edward
    Ben Simon, Guy J.
    Yassur, Iftach
    EYE, 2022, 36 (02) : 407 - 413
  • [27] EFFICACY AND SAFETY OF AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS: INTERIM RESULTS FROM THE OPEN-LABEL, SINGLE-ARM, PHASE 2 PATHFINDER STUDY
    Vannucchi, A. M.
    DeAngelo, D. J.
    Reiter, A.
    Radia, D.
    Deininger, M. W.
    George, T. I.
    Panse, J.
    Jentzsch, M.
    Alvarez-Twose, I.
    Mital, A.
    Hermine, O.
    Dybedal, I.
    Hexner, E. O.
    Hicks, L. K.
    Span, L.
    Mesa, R.
    Bose, P.
    Pettit, K. M.
    Heaney, M. L.
    Oh, S.
    Sen, J.
    Lin, H-M.
    Mar, B. G.
    Gotlib, J.
    HAEMATOLOGICA, 2021, 106 (10) : 2 - 2
  • [28] Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: A multicenter, open-label, single-arm phase II study
    Srimuninnimit, Vichien
    Sriuranpong, Virote
    Suwanvecho, Suthida
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 (03) : 255 - 260
  • [29] Cabozantinib in advanced renal cell carcinoma: A phase II, open-label, single-arm study of Japanese patients
    Tomita, Yoshihiko
    Tatsugami, Katsunori
    Nakaigawa, Noboru
    Osawa, Takahiro
    Oya, Mototsugu
    Kanayama, Hiroomi
    Kondoh, Chihiro Nakayama
    Sassa, Naoto
    Nishimura, Kazuo
    Nozawa, Masahiro
    Masumori, Naoya
    Miyoshi, Yasuhide
    Kuroda, Shingo
    Tanaka, Shingo
    Kimura, Akiko
    Tamada, Satoshi
    INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 (11) : 952 - 959
  • [30] Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study
    Hansson, Johan
    Bartley, Karen
    Karagiannis, Thomas
    Grob, Jean-Jacques
    Kunstfeld, Rainer
    Dreno, Brigitte
    Mortier, Laurent
    Ascierto, Paolo A.
    Licitra, Lisa
    Dutriaux, Caroline
    Thomas, Luc
    Meyer, Nicolas
    Guillot, Bernard
    Dummer, Reinhard
    Fife, Kate
    Ernst, D. Scott
    Yim, Yeun Mi
    Dimier, Natalie
    Fittipaldo, Alberto
    Basset-Seguin, Nicole
    Hauschild, Axel
    EUROPEAN JOURNAL OF DERMATOLOGY, 2018, 28 (06) : 775 - 783
12345